CS
CSBR
—
Nasdaq
Biotechnology & Life-Science Tools
Champions Oncology, Inc.
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
79,7M USD
P/E
—
EV / Rev
1,3x
Div yield
—
Op margin
-1,9 %
ROE
-29,8 %
Net margin
-2,0 %
Debt / equity
—
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
$5,26
Open
—
Next earnings
2026-08-28
Ex-dividend
—
TR 1Y
—
About
Champions Oncology, Inc. operates as a clinical-stage biopharmaceutical company focused on drug discovery and development, generating revenue through its technology platforms and Software as a Service (SaaS) offerings.
Business. Champions Oncology, Inc. (CSBR) is a biotechnology company focused on the development of novel therapies for cancer and other serious diseases. The firm operates within the Biotechnology & Life-Science Tools industry and does not report distinct operating segments or geographic breakdowns in the provided data. Headquartered in the United States, the company is listed on the Nasdaq stock exchange under the ticker symbol CSBR.
Classification99 %
SectorHealth Care
Industry groupBiotechnology & Life-Science Tools
Generated · model-assisted
Sell-side consensus
—consensus pending
— buy— hold— sell
Avg 12m price target—
At a glance
Score
—
not yet scored
Valuation
—
valuation pending
Analysts
—
not yet wired
Ownership→
Morgan Stanley Smith Barney LLC
largest disclosed fund holder
Profitability→
-29,8 %
return on equity
Quality
—
not yet scored
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
— missing data
News & coverage
0Sector rotation
Sector1D1Mvs mkt
Materials+2,3 %+6,6 %+1,7 %
Communication Services+2,2 %−5,5 %+1,6 %
Energy+0,6 %+3,3 %+0,0 %
Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
Information Technology+0,6 %+6,7 %+0,0 %
Consumer Discretionary+0,4 %+7,6 %−0,2 %
Financials−0,3 %−2,8 %−0,9 %
Consumer Staples−0,4 %+2,5 %−1,0 %
Real Estate−0,7 %+10,9 %−1,3 %
Industrials−1,9 %−3,1 %−2,5 %
Utilities−1,9 %+28,2 %−2,5 %
Developing storylines
No tracked sagas currently linked to CSBR. Browse all sagas →
Analysis
AI analysis
Generated · analysis pipeline · tier hybrid · as of 2026-08-04
↑ At a glance
Opportunity
— missing data
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ2 2026 earnings (expected)2026-08-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
— missing data
Signals & dispatch
peak dispatch · —
Composite-score breakdown
Synthesis
Business
Champions Oncology, Inc. (CSBR) is a biotechnology company focused on the development of novel therapies for cancer and other serious diseases. The firm operates within the Biotechnology & Life-Science Tools industry and does not report distinct operating segments or geographic breakdowns in the provided data. Headquartered in the United States, the company is listed on the Nasdaq stock exchange under the ticker symbol CSBR.
Classification99 %
SectorHealth Care
Industry groupBiotechnology & Life-Science Tools
AI synthesis
GENERATEDChampions Oncology maintains a capital structure characterized by zero debt and a current ratio of 0.96, indicating that current liabilities exceed current assets. The company holds $7.13 million in cash and equivalents against total assets of $26.99 million and total liabilities of $22.92 million. With a market capitalization of $82.72 million and a price-to-book ratio of 22.16, the equity valuation is significantly detached from tangible book value. The firm generated negative operating cash flow of -$4.47 million and free cash flow of -$5.04 million in FY2026, reflecting ongoing investment in research and infrastructure.
Profitability remains negative, with a net income of -$1.18 million and an operating income of -$1.14 million on revenues of $59.43 million. Return on equity stands at -29.83% and return on assets at -4.35%, signaling inefficient capital deployment relative to the asset base. The enterprise value to revenue multiple is 1.27x, while EV/EBITDA is elevated at 290.73x due to the lack of positive EBITDA. These metrics indicate a pre-profitability growth stage typical of early-phase biopharma entities.
Key takeaways
- Zero debt structure but negative cash flow of -$5.04M creates reliance on external financing.
- High dilution risk from outstanding stock options and potential future offerings.
- Volatile earnings with net income turning negative in FY2026 after positive results in FY2025.
- Regulatory uncertainty from FDA initiatives poses operational and timeline risks.
- Price action shows weakness with a new 52-week low on high volume.
Bull / Bear case
Generated · model-assistedBULL CASE · 5
Champions Oncology achieved positive free cash flow of $7 million in FY2025, marking a significant turnaround from prior negative cash generation.
The company's cash conversion ratio of 3.81 ranks as best-in-class compared to the biotechnology cohort median of 0.91.
Operating margin of -1.9% places Champions Oncology above the 75th percentile of its biotechnology and life-science tools cohort.
Revenue is projected to grow at a 6.6% compound annual growth rate from FY2024 to FY2026, indicating steady top-line expansion.
Net income surged 500.1% year-over-year in the latest period, demonstrating strong profitability improvement relative to the prior year.
BEAR CASE · 3
Champions Oncology faces high liquidity risk and a current ratio of 0.94, signaling potential difficulties in meeting short-term obligations.
The company carries a high leverage band with a debt-to-equity ratio of 7.57, indicating significant financial risk exposure.
Medium dilution risk exists for shareholders, potentially eroding equity value as the company seeks to fund operations or growth.
In focus — financials by report
Quarterly
Annual
QUARTERLYFiled 2026-01-31
Q4 2025 · Quarter highlights
Revenue $45.6M; Operating income -$618.0k.
Revenue$45.6M
Operating income-$618.0k
Net income-$508.0k
Free cash flow-$2.8M
EPS—
Operating cash flow-$2.5M
Financials
Income statement
Revenue$45.6M
Gross profit—
Operating income-$618.0k
Net income-$508.0k
Margins
Gross margin—
Operating margin-1.4%
Net margin-1.1%
FCF margin-6.1%
Balance sheet
Total assets$28.4M
Total liabilities$24.1M
Total equity$4.3M
Cash & equivalents$7.1M
Long-term debt—
Cash flow
Operating cash flow-$2.5M
CapEx$325.0k
Free cash flow-$2.8M
SBC$880.0k
P&L flow · revenue → net income
Highlights
- ▍Revenue $45.6M
- ▍Operating income -$618.0k
- ▍Net margin -1.1%
QUARTERLYFiled 2025-10-31
Q3 2025 · Quarter highlights
Revenue $29.0M; Operating income -$342.0k.
Revenue$29.0M
Operating income-$342.0k
Net income-$169.0k
Free cash flow-$1.4M
EPS—
Operating cash flow-$1.1M
Financials
Income statement
Revenue$29.0M
Gross profit—
Operating income-$342.0k
Net income-$169.0k
Margins
Gross margin—
Operating margin-1.2%
Net margin-0.6%
FCF margin-4.9%
Balance sheet
Total assets$30.2M
Total liabilities$25.9M
Total equity$4.2M
Cash & equivalents$8.5M
Long-term debt—
Cash flow
Operating cash flow-$1.1M
CapEx$288.0k
Free cash flow-$1.4M
SBC$457.0k
P&L flow · revenue → net income
Highlights
- ▍Revenue $29.0M
- ▍Operating income -$342.0k
- ▍Net margin -0.6%
QUARTERLYFiled 2025-07-31
Q2 2025 · Quarter highlights
Revenue $14.0M; Operating income -$527.0k.
Revenue$14.0M
Operating income-$527.0k
Net income-$436.0k
Free cash flow$554.0k
EPS—
Operating cash flow$600.0k
Financials
Income statement
Revenue$14.0M
Gross profit—
Operating income-$527.0k
Net income-$436.0k
Margins
Gross margin—
Operating margin-3.8%
Net margin-3.1%
FCF margin4.0%
Balance sheet
Total assets$30.5M
Total liabilities$27.0M
Total equity$3.5M
Cash & equivalents$10.3M
Long-term debt—
Cash flow
Operating cash flow$600.0k
CapEx$46.0k
Free cash flow$554.0k
SBC$208.0k
P&L flow · revenue → net income
Highlights
- ▍Revenue $14.0M
- ▍Operating income -$527.0k
- ▍Net margin -3.1%
ANNUALFiled 2026-04-30
FY 2026 · Full-year highlights
Revenue $59.4M; Operating income -$1.1M.
Revenue$59.4M
Operating income-$1.1M
Net income-$1.2M
Free cash flow-$5.0M
EPS—
Operating cash flow-$4.5M
Financials
Income statement
Revenue$59.4M
Gross profit—
Operating income-$1.1M
Net income-$1.2M
Margins
Gross margin—
Operating margin-1.9%
Net margin-2.0%
FCF margin-8.5%
Balance sheet
Total assets$27.0M
Total liabilities$22.9M
Total equity$3.9M
Cash & equivalents—
Long-term debt—
Cash flow
Operating cash flow-$4.5M
CapEx$564.0k
Free cash flow-$5.0M
SBC$1.2M
P&L flow · revenue → net income
Highlights
- ▍Revenue $59.4M
- ▍Operating income -$1.1M
- ▍Net margin -2.0%
ANNUALFiled 2025-04-30
FY 2025 · Full-year highlights
Revenue $56.9M; Operating income $4.6M.
Revenue$56.9M
Operating income$4.6M
Net income$4.7M
Free cash flow$7.0M
EPS—
Operating cash flow$7.4M
Financials
Income statement
Revenue$56.9M
Gross profit—
Operating income$4.6M
Net income$4.7M
Margins
Gross margin—
Operating margin8.0%
Net margin8.3%
FCF margin12.3%
Balance sheet
Total assets$32.3M
Total liabilities$28.6M
Total equity$3.8M
Cash & equivalents—
Long-term debt—
Cash flow
Operating cash flow$7.4M
CapEx$389.0k
Free cash flow$7.0M
SBC$654.0k
P&L flow · revenue → net income
Highlights
- ▍Revenue $56.9M
- ▍Operating income $4.6M
- ▍Net margin 8.3%
ANNUALFiled 2025-04-30
FY 2026 · Full-year highlights
Revenue $56.9M; Operating income $4.6M.
Revenue$56.9M
Operating income$4.6M
Net income$4.7M
Free cash flow$7.0M
EPS—
Operating cash flow$7.4M
Financials
Income statement
Revenue$56.9M
Gross profit—
Operating income$4.6M
Net income$4.7M
Margins
Gross margin—
Operating margin8.0%
Net margin8.3%
FCF margin12.3%
Balance sheet
Total assets$32.3M
Total liabilities$28.6M
Total equity$3.8M
Cash & equivalents—
Long-term debt—
Cash flow
Operating cash flow$7.4M
CapEx$389.0k
Free cash flow$7.0M
SBC$654.0k
P&L flow · revenue → net income
Highlights
- ▍Revenue $56.9M
- ▍Operating income $4.6M
- ▍Net margin 8.3%
ANNUALFiled 2024-04-30
FY 2024 · Full-year highlights
Revenue $50.2M; Operating income -$7.4M.
Revenue$50.2M
Operating income-$7.4M
Net income-$7.3M
Free cash flow-$7.0M
EPS—
Operating cash flow-$6.1M
Financials
Income statement
Revenue$50.2M
Gross profit—
Operating income-$7.4M
Net income-$7.3M
Margins
Gross margin—
Operating margin-14.7%
Net margin-14.5%
FCF margin-13.9%
Balance sheet
Total assets$26.1M
Total liabilities$28.0M
Total equity-$1.9M
Cash & equivalents—
Long-term debt—
Cash flow
Operating cash flow-$6.1M
CapEx$836.0k
Free cash flow-$7.0M
SBC$1.1M
P&L flow · revenue → net income
Highlights
- ▍Revenue $50.2M
- ▍Operating income -$7.4M
- ▍Net margin -14.5%
ANNUALFiled 2024-04-30
FY 2025 · Full-year highlights
Revenue $50.2M; Operating income -$7.4M.
Revenue$50.2M
Operating income-$7.4M
Net income-$7.3M
Free cash flow-$7.0M
EPS—
Operating cash flow-$6.1M
Financials
Income statement
Revenue$50.2M
Gross profit—
Operating income-$7.4M
Net income-$7.3M
Margins
Gross margin—
Operating margin-14.7%
Net margin-14.5%
FCF margin-13.9%
Balance sheet
Total assets$26.1M
Total liabilities$28.0M
Total equity-$1.9M
Cash & equivalents—
Long-term debt—
Cash flow
Operating cash flow-$6.1M
CapEx$836.0k
Free cash flow-$7.0M
SBC$1.1M
P&L flow · revenue → net income
Highlights
- ▍Revenue $50.2M
- ▍Operating income -$7.4M
- ▍Net margin -14.5%
Valuation FY
Market price
$5,76
Market cap
$82.7M
Enterprise valueⓘ
$75.6M
P/Eⓘ
—
Non-GAAP P/Eⓘ
—
EV / Revenueⓘ
1.3x
EV / Op incomeⓘ
—
EV / OCFⓘ
—
P / Bⓘ
22.2x
P / Tangible bookⓘ
22.2x
Tangible book
$3.7M
Net cashⓘ
$7.1M
Current ratioⓘ
1.0
Debt / equityⓘ
—
ROAⓘ
-4.3%
ROEⓘ
-29.8%
Cash conversionⓘ
381.0%
CapEx / revenueⓘ
0.9%
SBC / revenueⓘ
2.1%
Dilution ratioⓘ
-0.4%
Revenue by segment
Business relationships
— missing data
Supply chain
— missing data
Peer comparison
Peer comparison8 peers · vs CSBR · multiples and returns
IQ
IQV—
Iqvia Holdings Inc
$181,94
30,9B USDP/E
22,7x
— vs self
Div yield
—
— vs self
ROE
21,9 %
+51,7 vs self
CR
CRL—
Charles River Laboratories
$230,87
11,4B USDP/E
—
— vs self
Div yield
—
— vs self
ROE
-4,6 %
+25,3 vs self
ME
MEDP—
Medpace Holdings Inc
$576,00
16,7B USDP/E
34,4x
— vs self
Div yield
—
— vs self
ROE
75,4 %
+105,2 vs self
AL
ALKS—
Alkermes PLC
$49,53
8,2B USDP/E
39,8x
— vs self
Div yield
—
— vs self
ROE
8,4 %
+38,2 vs self
PI
PIII—
P3 Health Partners Inc
$10,20
73,8M USDP/E
—
— vs self
Div yield
—
— vs self
ROE
95,3 %
+125,1 vs self
OR
ORGO—
Organogenesis Holdings Inc
$2,38
306,2M USDP/E
9,0x
— vs self
Div yield
—
— vs self
ROE
8,5 %
+38,4 vs self
NA
NAGE—
Niagen Bioscience Inc
$3,53
281,1M USDP/E
17,4x
— vs self
Div yield
—
— vs self
ROE
22,7 %
+52,5 vs self
SP
SPRY—
Ars Pharmaceuticals Inc
$5,51
547,1M USDP/E
—
— vs self
Div yield
—
— vs self
ROE
-149,9 %
-120,1 vs self
Market position
Stress test
— missing data
Predictor forecast
Options
— missing data
Short squeeze
— missing data
Earnings-call key lines
— missing data
Estimate revisions
consensus EPS · 26-week trend— missing data
Sell-side observations
— missing data
Themes
— missing data
ESG
— missing data
Risk factors
Dilution riskMedium
Liquidity riskHigh
Filing-based flags
- Current liabilities exceed current assets.
- Source documents mention dilution or offering risk.
Benchmarks vs cohort
Op Margin-1,9 %Above P75
Net Margin-2,0 %Above median
ROE-29,8 %Below median
Capex / Rev0,9 %Above P75
D/E0,00Above median
Cash Conv3,81Best in class
Corporate actions / M&A
— missing data
FX exposure
— missing data
Comparable transactions
— missing data
Derivatives & instruments
Derivative transactions
Net acquired 1 067 sh1 exercises · 5 grants5 insiders
- Director · Option to purchase Common Stock → Common StockAcquired 21 216 @ $6,80grant · 2025-11-05
- Director, 10% owner · Option to purchase Common Stock → Common StockAcquired 25 460 @ $6,80grant · 2025-11-05
- Director · Option to purchase Common Stock → Common StockAcquired 13 790 @ $6,80grant · 2025-11-05
- Director · Option to purchase Common Stock → Common StockAcquired 21 216 @ $6,80grant · 2025-11-05
- Director · Option to purchase Common Stock → Common StockAcquired 13 790 @ $6,80grant · 2025-11-05
- Director · Option to purchase Common Stock → Common StockDisposed 94 405 @ $2,10exercise · 2025-10-30
Actions
Ask Handelsavisen
— missing data
Data sources
- Market data
- Regulatory filings
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Reference data
How metrics are computed
- Cash Conversion Ratiooperating_cash_flow / net_income
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Ev To Revenueenterprise_value / revenue
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Return On Equitynet_income / total_equity
- Market Capmarket_price * shares_outstanding_diluted
Source documents
- CHAMPIONS ONCOLOGY, INC. company facts · 2026-08-02
- CHAMPIONS ONCOLOGY, INC. 10-K 2026-07-27 · 2026-08-02
- CHAMPIONS ONCOLOGY, INC. 10-Q 2026-03-12 · 2026-08-02
- CHAMPIONS ONCOLOGY, INC. 10-Q 2025-12-15 · 2026-08-02
- CHAMPIONS ONCOLOGY, INC. 10-Q 2025-09-15 · 2026-08-02
- ha_price_52w fired on CSBR · 2026-08-02
- Champions Oncology Inc Market data — analyst estimates · 2026-08-02
- Champions Oncology Inc Market data — ESG · 2026-08-02
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2025-12-310,00 %$2M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2024-06-300,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$0M
Insider activity
Mixed / flat0 buys · 0 sellsnet $01 insiders · last 365d
- Director · Common StockOther 94 405 @ $2,10$198K · 2025-10-30
Short positioning
75.6Kshares short-1.8% vs prior
7.85days to cover
24.9%short of daily vol
3fails-to-deliver
as of 2026-07-15 · short-interest report (free)
Geographic breakdown
— missing data
Listings · one canonical issuer
all listings resolve to the canonical
CSBRCanonical
Nasdaq · USD
Intel & risk
peak dispatch · —
OSINT findings
Dilution riskMedium
Liquidity riskHigh
Current liabilities exceed current assets.
Source documents mention dilution or offering risk.
Evidence & claims
From filings & derived data- Operating cash flow (annual): USD -4.47MUnknown
- Pre-tax income (annual): USD -929KUnknown
- Net income (annual): USD -1.18MUnknown
- Capex (annual): USD 564KUnknown
- Cost of revenue (annual): USD 30.9MUnknown
- Operating income (annual): USD -1.14MUnknown
- Revenue (annual): USD 59.42MUnknown
- EPS (basic) (annual): USD-PER-SHARES -0Unknown
- R&D expense (annual): USD 9.08MUnknown
- EPS (diluted) (annual): USD-PER-SHARES -0Unknown
- Debt-to-equity (FY 2026-01-31): 5.62xDerived (calculated)
- Current ratio (FY 2026-01-31): 0.98xDerived (calculated)
- Cash & equivalents (YoY) (2026-01-31 vs 2025-01-31): 122.6%Derived (calculated)
- Shareholders' equity (YoY) (2026-01-31 vs 2025-01-31): -21.7%Derived (calculated)
- Total liabilities (YoY) (2026-01-31 vs 2025-01-31): -4.3%Derived (calculated)
- Total assets (YoY) (2026-01-31 vs 2025-01-31): -7.1%Derived (calculated)
- Total assets (annual): USD 28.45MSEC XBRL filing
- Current assets (annual): USD 20.18MSEC XBRL filing
- Total liabilities (annual): USD 24.07MSEC XBRL filing
- Current liabilities (annual): USD 20.68MSEC XBRL filing
- Shareholders' equity (annual): USD 4.28MSEC XBRL filing
- Shares outstanding (annual): 13.89MSEC XBRL filing
- Cash & equivalents (annual): USD 7.13MSEC XBRL filing
- Operating cash flow (YoY) (2025-04-30 vs 2024-04-30): 220.4%Derived (calculated)
Showing 24 of 60 surfaced claims.
Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.
The Thread
Everything we know, in order2026-08-28EVENTUpcomingQ2 2026 earnings (expected) estimated date
2026-07-30 21:51 UTCEVENTHa Price 52W CSBR printed a new 52-week low on elevated volume (x5.449)
2026-07-27 00:00 UTCTRANSCRIPTEarnings call — Q3 2026
2026-07-27EVENTQ2 2026 earnings (expected) estimated date
2026-04-30EARNINGSAnnual results — FY 2026 Revenue USD 59.4M · Net USD -1.2M
2026-01-31EARNINGSQuarterly results — Q4 2025 Revenue USD 45.6M · Net USD -0.5M
2025-11-05 00:00 UTCINSIDER5 insider transactions — 2025-11 5 derivative
2025-11-05INSIDERACKERMAN JOEL acquired 21.2k sh Option to purchase Common Stock — Director
2025-11-05INSIDERTOBIN SCOTT R acquired 25.5k sh Option to purchase Common Stock — Director, 10% owner
2025-11-05INSIDERMendelson Daniel Newman acquired 13.8k sh Option to purchase Common Stock — Director
2025-11-05INSIDERSIDRANSKY DAVID acquired 21.2k sh Option to purchase Common Stock — Director
2025-11-05INSIDERBreitfeld Philip P. acquired 13.8k sh Option to purchase Common Stock — Director
2025-10-31EARNINGSQuarterly results — Q3 2025 Revenue USD 29.0M · Net USD -0.2M
2025-10-31EARNINGSQuarterly results — Q3 2025
2025-10-30 00:00 UTCINSIDER2 insider transactions — 2025-10 · net buy $198k 1 derivative
2025-10-30INSIDERACKERMAN JOEL transacted 94.4k sh — Director ~$198k
2025-10-30INSIDERACKERMAN JOEL disposed of 94.4k sh Option to purchase Common Stock — Director
2025-07-31EARNINGSQuarterly results — Q2 2025 Revenue USD 14.0M · Net USD -0.4M
2025-07-16 00:00 UTCINSIDER4 insider transactions — 2025-07 4 derivative
2025-04-30EARNINGSAnnual results — FY 2025 Revenue USD 56.9M · Net USD 4.7M
2025-03-25 00:00 UTCINSIDER1 insider transaction — 2025-03
2024-11-12 00:00 UTCINSIDER6 insider transactions — 2024-11 6 derivative
2024-10-31 00:00 UTCINSIDER4 insider transactions — 2024-10 · net buy $276k 2 derivative
2024-04-30EARNINGSAnnual results — FY 2024 Revenue USD 50.2M · Net USD -7.3M
2024-01-12 00:00 UTCINSIDER7 insider transactions — 2024-01
2023-11-03 00:00 UTCINSIDER1 insider transaction — 2023-11 1 derivative
The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04
Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data · Reference data
Premium coverage